Group 1 - The core viewpoint of the news highlights the strong performance of the Hang Seng Biotechnology ETF (513280), which has seen a continuous inflow of funds and is the only ETF in its index to achieve net inflow this year [1][8] - WuXi AppTec announced a projected revenue growth of over 60% and an adjusted net profit growth of over 67% for the first half of 2025, driven by strong downstream demand for antibody-drug conjugates and a solid market position [3][5] - The performance of the underlying stocks in the Hang Seng Biotechnology ETF is mixed, with notable gains in the CRO sector, including WuXi AppTec rising over 10% and WuXi Biologics increasing nearly 3% [3][4] Group 2 - Zhongtai Securities indicates that the CRO and CDMO sectors have exceeded expectations in their mid-year performance, suggesting a recovery in demand and potential for profit and valuation increases [5][6] - The report emphasizes the importance of focusing on the recovery of the CRO and CDMO sectors, with signs of improving orders and a gradual recovery in the investment environment [6][7] - The innovation and recovery themes are highlighted as key investment lines, with a focus on innovative drugs and medical devices, as well as the recovery of the CXO sector [7][8]

7月23日，港股创新药继续猛攻，高纯度+高弹性标的港股通创新药ETF（520880）场内价格续涨逾 2%，实时成交额1．4亿元，交投活跃。 | 序号 | 代码 | 名称 | 两日图 | 现价 | 派跌 | 4 涨跌幅 | | --- | --- | --- | --- | --- | --- | --- | | 1 | 2268 | 药明合联 | 1 | 54.800 | 5.400 | 10.93% | | 2 | 2157 | 乐普生物-B | w | 8.160 | 0.780 | 10.57% | | 3 | 1548 | 金斯瑞生物科技 | formal | 18.780 | 1.760 | 10.34% | | 4 | 2186 | 绿叶制药 | para | 3.860 | 0.210 | 5.75% | | ਟ | 2269 | 药明生物 | 100 | 29.250 | 1.250 | 4.46% | | 6 | 6160 | 百济神州 | Ma | 182.600 | 6.400 | 3.63% | | 7 | 0512 | 远大医药 | May | 9.740 | 0.340 | 3.6 ...

Group 1 - The core viewpoint indicates a strong recovery signal in the CXO sector, with multiple companies showing positive performance and growth expectations [1] - WuXi AppTec forecasts over 60% year-on-year revenue growth and over 67% adjusted net profit growth for the first half of 2025, with net profit expected to grow over 50% [1] - The CXO sector is gradually emerging from a low point, with several companies demonstrating signs of recovery, supported by favorable factors such as potential interest rate cuts by the Federal Reserve and improved financing conditions in the pharmaceutical sector [1] Group 2 - The Medical Innovation ETF has shown a 10.56% increase over the past three months and a 17.26% return over the past year, outperforming industry benchmarks [2] - The total healthcare expenditure in China is expected to continue stable and sustainable growth, with a focus on identifying sub-sectors that grow faster than the industry average as a source of excess investment returns [2] - Innovation remains a perpetual theme and long-term driving force in the pharmaceutical industry, with the Medical Innovation ETF providing an opportunity to capture undervalued leading companies [2]

流动性方面，恒生医疗ETF盘中换手22.89%，成交18.79亿元，市场交投活跃。拉长时间看，截至7月22 日，恒生医疗ETF近1周日均成交30.29亿元，排名可比基金第一。 消息面上，2025年7月23日，药明合联股价高开，盘中涨超12%创上市新高，业绩预期强劲。公司预计 2025年上半年收入同比增超60%，经调整净利润增超67%，净利润增超50%，主因ADC及生物偶联药需 求旺盛，新产线产能爬坡快、利用率高。 国信证券指出，上周生物医药板块整体上涨4.00%，估值处于近五年历史分位的78.75%，显示出市场对 板块的持续关注度。创新药板块在海外市场持续改善的背景下，国产创新药在多个国际学术会议中展示 出优秀的临床数据，出海趋势不断加强，建议关注具备高质量创新能力的标的。 规模方面，恒生医疗ETF近2周规模增长5636.13万元，实现显著增长，新增规模位居可比基金1/3。 数据显示，杠杆资金持续布局中。恒生医疗ETF前一交易日融资净买额达2106.00万元，最新融资余额 达2.52亿元。 截至7月22日，恒生医疗ETF近2年净值上涨30.23%。从收益能力看，截至2025年7月22日，恒生医疗 ETF自成立 ...

Market Overview - The Hang Seng Index is expected to rise towards 26,000 points due to a stable economic outlook in mainland China and active market trading, despite limited corporate profit improvements [2] - The market remains active with a positive risk appetite, as funds rotate across different sectors [2] Macro Focus - Sweden will host a new round of US-China trade negotiations, with the aim of extending the tariff suspension period [4][7] - The US has reached a trade agreement with Japan, reducing tariffs to 15% and involving a $550 billion investment from Japan [7] - China's foreign exchange bureau reported a net increase of $10.1 billion in foreign investment in A-shares and funds in the first half of the year, indicating a stable growth outlook for foreign capital [8] Company News - Chow Tai Fook (1929) reported a 1.9% year-on-year decline in retail value for the first fiscal quarter [4] - TCL Electronics (1070) expects a mid-term adjusted net profit increase of up to 65% year-on-year, driven by quality growth in core business and improved product and channel structure [9] - ASMPT (0522) reported a 32% decrease in mid-term profit, with a dividend of 0.26 HKD per share [9] - WuXi AppTec (2268) anticipates a mid-term net profit growth of over 50% [4] - The Fourth Paradigm (6682) has launched Phancy AI smart glasses, with shipments expected in early August [9] Industry Insights - The Chinese smartphone market saw a 2.4% year-on-year decline in shipments in Q2, influenced by early product launches due to subsidy policies [8] - The gaming industry in China continues to see regulatory stability, with 134 new game licenses issued in July, including notable titles like NetEase's "Diablo IV" [8]

Group 1 - The core viewpoint highlights the strong performance of the innovative drug ETFs, with Tianhong Innovative Drug ETF (517380) leading the industry with a 1.89% increase and a total trading volume of 4.6489 million yuan on July 23, 2025 [2] - The Tianhong Innovative Drug ETF has seen a cumulative increase of 3.93% over the past week, indicating positive momentum in the sector [2] - The Biopharmaceutical ETF (159859) also showed a 1.50% increase with a trading volume of 40.8703 million yuan, reflecting strong investor interest [2] Group 2 - The Biopharmaceutical ETF (159859) has achieved a 2.84% increase over the past week, ranking first among comparable funds, with an average daily trading volume of 110 million yuan [3] - The Biopharmaceutical ETF has experienced a significant growth of 543 million yuan in scale over the past year, indicating robust demand [3] - Guotai Junan Securities continues to recommend the innovative drug sector, citing improvements in both domestic and overseas markets, with new insurance directories supporting innovative drug development [3] Group 3 - The collaboration between stable operation of medical insurance funds and optimized centralized procurement policies is positively impacting the innovative drug industry, enhancing patient accessibility and market demand [4] - Recent trends show that multiple pharmaceutical companies are successfully launching innovative drugs overseas, validating China's R&D capabilities [4] - The Tianhong Innovative Drug ETF (517380) is noted as the only ETF tracking the Hang Seng-Hushen-Hong Kong Innovative Drug Select 50 Index, providing comprehensive coverage of A-shares and Hong Kong stocks [4]

Group 1 - The Hong Kong pharmaceutical stocks have shown strong performance, with Fangda Holdings (01521.HK) rising by 23.19%, Clover Biopharmaceuticals-B (02197.HK) increasing by 17.65%, Lepu Biopharma-B (02157.HK) up by 11.25%, and WuXi AppTec (02268.HK) gaining 9.41% [1] - WuXi AppTec is expected to see a more than 67% growth in adjusted net profit for the mid-term [1]

Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Positive" [2] Core Insights - The pharmaceutical and biotechnology sector has shown a weekly return of 4.00%, outperforming the CSI 300 by 2.91%, ranking second among 31 primary sub-industry indices [3][8] - The report emphasizes the importance of innovation and recovery as key investment themes, highlighting the ongoing enthusiasm for innovative drugs driven by policy incentives and clinical data [10] - Notable mergers and acquisitions, such as China Biopharmaceutical's acquisition of Lixin Pharmaceutical for approximately $1 billion, are seen as significant milestones in the industry [9][10] Summary by Sections 1. Industry Overview - The pharmaceutical and biotechnology sector's monthly return was 9.44%, ranking fourth among 31 primary sub-industry indices, with the medical services sub-sector leading with a 15.72% increase [8][22] - The chemical pharmaceuticals sub-sector had the highest weekly return of 6.86% [32] 2. Market Performance and Valuation - The current PE (TTM) for the pharmaceutical and biotechnology industry is 30.03, which is below the historical average of 30.89 [14][17] - The industry has shown a 21.25% increase over the last six months, outperforming the CSI 300 by 14.79% [12][14] 3. Stock Performance - Top-performing stocks in the past week include Borui Pharmaceutical, Lisheng Pharmaceutical, and Nanxin Pharmaceutical, with increases of 42.35%, 41.68%, and 34.95% respectively [37] - In the Hong Kong market, stocks like Sanofi Biologics and Lepu Medical have also shown significant gains of 63.79% and 62.04% [41] 4. Industry and Company Dynamics - Recent policy developments include the Shanghai Municipal Drug Administration's action plan for regulating online drug sales from 2025 to 2027 [44] - The National Healthcare Security Administration has initiated the eleventh batch of centralized drug procurement, which will include 55 varieties [44]

2025 年 07 月 20 日 投资评级：看好（维持） 医药生物 行业走势图 -24% -12% 0% 12% 24% 36% 2024-07 2024-11 2025-03 医药生物 沪深300 数据来源：聚源 相关研究报告 《CXO 龙头中报业绩超预期，重点关 注板块后续行情 — 行 业 周 报 》 -2025.7.13 《艾伯维收购 Capstan，加码体内 CAR-T—行业周报》-2025.7.6 《多款减肥药亮相 2025 ADA，重点关 注 AMYR 与 ActRII 靶点—行业周报》 -2025.6.29 集采政策明确优化，继续推荐制药板块性机会 ——行业周报 | 余汝意（分析师） | 刘艺（联系人） | 聂媛媛（联系人） | | --- | --- | --- | | yuruyi@kysec.cn | liuyi1@kysec.cn | nieyuanyuan@kysec.cn | | 证书编号：S0790523070002 | 证书编号：S0790124070022 | 证书编号：S0790124050002 | 集采政策持续优化，仿创 pharma 有望估值重塑 集采政策优化基调明确， ...

Core Insights - The report highlights the significant growth potential in the measurement and calibration industry, driven by new policies aimed at enhancing manufacturing capabilities in China [6][7][8] - The renewable energy sector, particularly in electric power equipment, is poised for growth due to supportive policies in the UK and increasing demand for energy storage solutions [13] - The pharmaceutical industry is recommended for investment, focusing on innovative drugs and their supply chains, with strong support from health insurance reforms [14] Industry and Company Analysis - **Measurement and Calibration Industry**: The first policy document from the Ministry of Industry and Information Technology emphasizes the need for precise measurement to drive innovation in manufacturing. This includes establishing a service network and digital transformation paths, with a focus on high-level calibration institutions and digital measurement software [6][7] - **Renewable Energy Sector**: The UK government has restarted subsidies for electric vehicles and charging infrastructure, indicating a robust market for energy storage systems. The report suggests focusing on companies involved in battery production and charging infrastructure, such as Ningde Times and Keda Technology [13] - **Pharmaceutical Industry**: The report continues to recommend innovative drug sectors, highlighting the recent adjustments in health insurance and commercial insurance that favor high-value innovative drugs. Companies like Kelun-Biotech and Innovent Biologics are noted for their strong potential in both domestic and international markets [14] - **Oil and Gas Sector**: China National Offshore Oil Corporation (CNOOC) has made significant advancements in oil and gas exploration, achieving record production levels in both domestic and international operations. The report anticipates continued growth in production capacity, particularly in the Stabroek block in Guyana [20][21][24]